UC Berkeley Fends off DTC Genomics Critics; Other Schools Mull Genetic Tests as Educational Tools
By Turna Ray,
GenomeWeb
| 05. 25. 2010
[Quotes CGS]
[updated May 26]
Going ahead with its plans to offer voluntary genetic testing to incoming freshman, the University of California, Berkeley, seems to not be deterred by numerous detractors of the direct-to-consumer genomics model who have criticized the effort.
UC Berkeley last week announced its plan to launch a voluntary program this fall that will test students in the Class of 2014 for three genes involved in the metabolization of alcohol, lactose, and folates. The announcement capped several controversial weeks for the DTC genomics sector, during which the marketing practices of Pathway Genomics brought regulatory action from the US Food and Drug Administration and spurred a congressional probe into the consumer genomics industry (PGx Reporter 05/19/10).
Upon announcing its gene testing plans as part of its "On the Same Page" program intended to introduce incoming students to an intellectual or thought-provoking experience, at least two organizations, the Center for Genetics and Society and the Council for Responsible Genetics, urged UC Berkeley to halt its plans.
In a statement on the CGS website, an analyst from the center pointed...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
